Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
News
ASX Small Caps & IPO Weekly Wrap: ASX dips 2.2pc and everyone Torqued like a pirate at Penzance
News
Rise and Shine: Everything you need to know before the ASX opens
News
In Case You Missed It: Rare earths on the rise, and coal seam gas pilot spudded
News
ASX Small Caps Lunch Wrap: Who else is feeling the Real Estate rage today?
News
Top 10 at 11: Emyria soars on funding news, and loads of tasty stuff unearthed in Canada.
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Recce Pharma jumps 20pc after saying its gel could heal antibiotic-resistant infections
Health & Biotech
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
News
CLOSING BELL: And just like that, all the magic was gone leaving the ASX flat today
Health & Biotech
Weed Week: Storm before the calm as cannabis market set to boom after SAFE Banking Act passed
Health & Biotech
ASX Health Stocks: Avita jumps 14pc on FDA approval; Emyria to start trial on landmark MDMA therapy
Health & Biotech
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
Health & Biotech
Could these Aussie psychedelics stocks carve a slice out of a ‘potential $63 billion’ global market?
News
CLOSING BELL: Nobody’s quite game to pick the bottom after the ASX makes it 5 losses on the trot
Health & Biotech
Weed Week: 420 reminds us that cannabis stocks may be down, but by no means out
News
Market Highlights: Solid start to the US earnings season, and 5 ASX small caps to watch on Tuesday
Health & Biotech
